Fractures in women treated with raloxifene or alendronate: A retrospective database analysis

BMC Women's Health

Volumn 13, Issue 1, 2013, Pages

  Foster, Shonda A ^a   Shi, Nianwen ^b   Curkendall, Suellen ^b   Stock, John ^a   Chu, Bong Chul ^b   Burge, Russel ^a   Diakun, David R ^b   Krege, John H ^c  

^a ELI LILLY AND COMPANY   (United States)

^b IBM WATSON HEALTH   (United States)

^c Lilly USA   (United States)

Author keywords

Alendronate; Breast cancer; Nonvertebral fracture; Raloxifene; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; RALOXIFENE;

ADULT; ARTICLE; BONE DENSITY; BREAST CANCER; COHORT ANALYSIS; DRUG EFFICACY; EMERGENCY CARE; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; PATHOLOGIC FRACTURE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROBABILITY; RETROSPECTIVE STUDY; RISK REDUCTION; SPINE FRACTURE; TREATMENT DURATION;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RALOXIFENE; RETROSPECTIVE STUDIES; UNITED STATES; WOMEN'S HEALTH;

EID: 84875147170     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-13-15     Document Type: Article

References (25)

1. National Osteoporosis Foundation 2010, http://www.nof.org/learn/basics, National Osteoporosis Foundation.
2. Riggs BL, Melton LJ. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995, 17(5 Suppl):505S-511S.
3. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19(4):385-397. 10.1007/s00198-007-0543-5, 2267485, 18292978.
4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22(3):465-475.
5. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348(9041):1535-1541. 10.1016/S0140-6736(96)07088-2, 8950879.
6. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280(24):2077-2082. 10.1001/jama.280.24.2077, 9875874.
7. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282(7):637-645. 10.1001/jama.282.7.637, 10517716.
8. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87(3):985-992. 10.1210/jc.87.3.985, 11889149.
9. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281(23):2189-2197. 10.1001/jama.281.23.2189, 10376571.
10. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001, 65(2):125-134. 10.1023/A:1006478317173, 11261828.
11. Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Stock JL. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 2007, 40(4):843-851. 10.1016/j.bone.2006.11.001, 17182297.
12. Shi N, Foley K, Lenhart G, Badamgarav E. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 2009, 45(6):1084-1090. 10.1016/j.bone.2009.07.086, 19664735.
13. Curtis JR, Taylor AJ, Matthews RS, Ray MN, Becker DJ, Gary LC, Kilgore ML, Morrisey MA, Saag KG, Warriner A, Delzell E. "Pathologic" fractures: should these be included in epidemiologic studies of osteoporotic fractures?. Osteoporos Int 2009, 20(11):1969-1972. 10.1007/s00198-009-0840-2, 2766025, 19184268.
14. Meijer WM, Beest FJ, Olson M, Herings RM. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. Curr Med Res Opin 2008, 24(11):3217-3222. 10.1185/03007990802470241, 18922215.
15. Imbens G. The role of the propensity score in estimating dose-response functions. Biometrika 2000, 87(3):706-710.
16. Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007, 45(10 Supl 2):S103-S107.
17. Hirano KIG. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Services & Outcomes Research Methodology 2001, 2:259-278. 10.1023/A:1020371312283, 23573543.
18. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008, 27(12):2037-2049. 10.1002/sim.3150, 18038446.
19. Yang YYZ. Marginal proportional hazards models for multiple event-time data. Biometrika 2001, 88:581-586.
20. Austin PC, MMamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 2006, 25(12):2084-2106. 10.1002/sim.2328, 16220490.
21. Cadarette SM, Katz JN, Brookhart MA, Sturmer T, Stedman MR, Solomon DH. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 2008, 148(9):637-646. 3285566, 18458276.
22. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N. Effectiveness of bisphosphonate therapy in a community setting. Bone 2009, 44(1):153-159. 10.1016/j.bone.2008.09.006, 18926939.
23. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002, 87(8):3609-3617. 10.1210/jc.87.8.3609, 12161484.
24. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010, 102:799-802. 10.1038/sj.bjc.6605555, 2833248, 20160722.
25. Foster SA, Foley KA, Meadows ES, Johnston JA, Wang S, Pohl GM, Long SR. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC Womens Health 2008, 8:24. 10.1186/1472-6874-8-24, 2642779, 19105828.